Drug Combination Details
| General Information of the Combination (ID: C58834) | |||||
|---|---|---|---|---|---|
| Name | Betulinic Acid NP Info | + | Imatinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Chronic myelogenous leukaemia
[ICD-11: 2A20]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Up-regulation | HDAC3 ubiquitination and degradation | ||||
| In-vitro Model | K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation. | |||||
